Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 3, 1998, Pages 226-232

  Kourousis, Charalambos ^a   Kakolyris, Stelios ^a   Androulakis, Nicos ^a   Heras, Panagiotis ^a   Vlachonicolis, John ^a   Vamvakas, Lambros ^a   Vlata, Maria ^a   Hatzidaki, Dora ^a   Samonis, George ^a   Georgoulias, Vassilis ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Anthracycline resistance; Breast cancer; Cisplatin; Paclitaxel; Salvage chemotherapy; Vinorelbine

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CISPLATIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG RESISTANCE; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; NEUROTOXICITY; NEUTROPENIA; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PATIENT COMPLIANCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TAXOIDS; VINBLASTINE;

EID: 0031814778     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199806000-00003     Document Type: Article

References (33)

1. Clark GM, Sledge GW, Osboe CK, et al. Survival from first reccurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 1987;5:5-61.
2. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1779-805.
3. Reichman BC, Seidman AD, Grown JPA, et al. Taxol and recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993;11:1943-51.
4. Seidman AD, Reichman BS, Grown JPA, et al. Paclitaxel as second and subsequent chemotherapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995;13:1152-9.
5. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994;12:1621-9.
6. Fountzilas G, Athanassiades A, Giannakakis T, et al. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 1996;32A:47-51.
7. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67.
8. Abrams JS, Tiersten A, Hudis C, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995;13:2056-65.
9. Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-81.
10. Klaassen U, Wilke H, Strumberg D, et al. Phase I study with a weekly 1h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 1996;32A:547-9.
11. Dieras V, Marty M, Tubiana N, et al. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 1995;22(suppl 8):33-9.
12. Gianni L, Munzone E, Capri G, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995;87:1169-75.
13. Mageney P, Andriamilisoa RZ, Lallemand JY, et al. 5′ noranhydrovinblastine. prototype of a new class of vinblastine derivates. Tetrahedron 1979;35:2175-9.
14. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-52.
15. Garcia-Conde J, Lluch A, Martin M, et al. Phase II trial of weekly vinorelbine in first line advanced breast cancer. Ann Oncol 1994;5:854-7.
16. Romero A, Rabinovich MG, Vallejo CT, et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994;12:336-41.
17. Toussaint C, Izzo J, Spielman M, et al. Phase I/II trial of continuous infusion of vinorelbine for advanced breast cancer. J Clin Oncol 1994;12:2102-12.
18. Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995;13:2567-74.
19. Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722-30.
20. Gasparini G, Caffo O, Bai S, et al. Vinorelbine as an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994;12:2094-101.
21. Kolaric K, Roth A. Phase II clinical trial of cisdichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983;11:108-12.
22. Sledge GW, Loehrer PJ, Roth BJ, et al. Cisplatin as first line therapy for metastatic breast cancer. J Clin Oncol 1988;6:1811-4.
23. Yap HY, Salem P, Hortobagyi GN, et al. Phase II study of cisdichlorodiammineplatinum in advanced breast cancer. Cancer Treat Rep 1978;62:405-8.
24. Forastiere AA, Hakes TB, Wittes JT, et al. Cisplatin in the treatment of metastatic breast cancer. Am J Clin Oncol 1982;5:243-7.
25. Hamel E, del Campo AA, Lowe MC, Lin C. Interactions of taxol, microtubule-associated proteins and guanine nucleotides in tubulin polymerization. J Biol Chem 1981;256:11887-94.
26. Zavala F, Guenard D, Potier P. Interaction of vinblastine analogues with tubulin. Separatium Experiential 1978;34:1497-8.
27. Hortobagyi GN, Ibrahim N. Paclitaxel-containing chemotherapy for metastatic breast cancer. Semin Oncol 1996;23(suppl 2):53-7.
28. Gelman KA, O'Reilly SE, Tolcher AW, et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996;14:1185-91.
29. Depierre A, Chastang CL, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small-cell lung cancer. a randomized trial. Ann Oncol 1994;5:37-42.
30. Wozniak AJ, Kromlay JJ, Balcerzak GR, et al. Randomized phase III trial of cisplatin (CDDP) vs CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): report of a Southwest Oncology Group study (SWOG 9308) [Abstract]. Proceedings of the American Society of Clinical Oncology 1996;15:374.
31. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
32. Wasserheit C, Frazein A, Oratz R, et al. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 1996;14:1993-9.
33. Binet S, Chinhau E, Fellous A, et al. Immunofluorescence study of the action of vinorelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer 1990;46:262-6.